Get started
Author

Sumanta Monty Pal

Observed name: Sumanta Pal
OpenAlex ID: A5070032327
Abstract CT011: A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)
2023 · Samer Srour, Ritesh Kotecha, et al. · Cancer Research · 38
558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study
2022 · Sumanta Pal, Ben Tran, et al. · Regular and Young Investigator Award Abstracts · 29
PDF
Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC).
2023 · Yu-Wei Chen, Katy Beckermann, et al. · Journal of Clinical Oncology · 17
Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC).
2023 · Matt D. Galsky, Siamak Daneshmand, et al. · Journal of Clinical Oncology · 17
PDF
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium
2025 · James P Blackmur, J C Koen van der Mijn, et al. · The Lancet Oncology · 11
Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC).
2023 · Toni K. Choueiri, Jens Bedke, et al. · Journal of Clinical Oncology · 10
Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma
2025 · Michael Grant, Barbara Cipriani, et al. · Cancers · 5
PDF
322 ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): updated safety and efficacy from the phase 1 TRAVERSE multicenter study
2024 · Samer A Srour, Jad Chahoud, et al. · Regular and Young Investigator Award Abstracts · 5
Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).
2023 · Nazli Dizman, Ameish Govindarajan, et al. · Journal of Clinical Oncology · 5
Improved health-related quality of life (HR-QOL) with use of an online mindfulness tool in patients with metastatic renal cell carcinoma (mRCC) receiving immunotherapy (IO).
2023 · Cristiane Decat Bergerot, Jasnoor Malhotra, et al. · Journal of Clinical Oncology · 5
Cabozantinib in combination with atezolizumab in non-clear cell renal cell carcinoma: Extended follow-up results of cohort 10 of the COSMIC-021 study.
2023 · Bradley Alexander McGregor, Neeraj Agarwal, et al. · Journal of Clinical Oncology · 5
PDF
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma
2024 · Justine Panian, Caiwei Zhong, et al. · European Urology Focus · 4
Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
2023 · Kosuke Takemura, Audreylie Lemelin, et al. · Journal of Clinical Oncology · 4
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers
2025 · Rana R. McKay, Sumanta Pal, et al. · CA A Cancer Journal for Clinicians · 3
PDF
Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma
2025 · Yasser Ged, Amina Touma, et al. · Journal of Immunotherapy · 3
Financial toxicity in patients with metastatic renal cell carcinoma on combination therapy.
2023 · Michael D. Staehler, Hedyeh Ebrahimi, et al. · Journal of Clinical Oncology · 3
Patient perceptions of benefits and risks of adjuvant therapy in renal cell carcinoma.
2023 · Dena Battle, Pavlos Msaouel, et al. · Journal of Clinical Oncology · 3
PDF
17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433)
2025 · Chet Bohac, Sumanta Pal, et al. · The Oncologist · 2
PDF
667 A phase 1, multiple-dose study to evaluate the safety and tolerability of XmAb®819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (RCC)
2022 · Sumanta Pal, Sreeni Yalamanchili, et al. · Regular and Young Investigator Award Abstracts · 2
PDF
Correction: Grant et al. Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma. Cancers 2025, 17, 3883
2026 · Michael Grant, Barbara Cipriani, et al. · Cancers · 1
PDF
The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
2023 · Daniela Castro, Nishita Tripathi, et al. · The Oncologist · 1
PDF
Abstract B019: Clinical and molecular characterization of chromophobe renal cell carcinoma: A focus on immunotherapy based regimens and the tumor immune microenvironment
2023 · Michel Alchoueiry, Chris Labaki, et al. · Cancer Research · 1
Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.
2023 · Chris Labaki, Ziad Bakouny, et al. · Journal of Clinical Oncology · 1
19 Dissecting ARNT Expression Patterns in RCC and Association with Outcomes
2026 · Yu-Wei Chen, Shayan Nazari, et al. · The Oncologist
PDF
Works count: 55
Citation count: 192
H-index: 7
I10-index: 7
Year
Topic
Type